195 related articles for article (PubMed ID: 24777276)
21. Natural history of multiple sclerosis: risk factors and prognostic indicators.
Vukusic S; Confavreux C
Curr Opin Neurol; 2007 Jun; 20(3):269-74. PubMed ID: 17495619
[TBL] [Abstract][Full Text] [Related]
22. Age is a critical determinant in recovery from multiple sclerosis relapses.
Conway BL; Zeydan B; Uygunoğlu U; Novotna M; Siva A; Pittock SJ; Atkinson EJ; Rodriguez M; Kantarci OH
Mult Scler; 2019 Nov; 25(13):1754-1763. PubMed ID: 30303037
[TBL] [Abstract][Full Text] [Related]
23. Multiple sclerosis: relapses and timing of remissions.
Iuliano G; Napoletano R; Esposito A
Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis.
Binquet C; Quantin C; Le Teuff G; Pagliano JF; Abrahamowicz M; Moreau T
Neuroepidemiology; 2006; 27(1):45-54. PubMed ID: 16825794
[TBL] [Abstract][Full Text] [Related]
25. Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Hughes SE; Spelman T; Gray OM; Boz C; Trojano M; Lugaresi A; Izquierdo G; Duquette P; Girard M; Grand'Maison F; Grammond P; Oreja-Guevara C; Hupperts R; Bergamaschi R; Giuliani G; Lechner-Scott J; Barnett M; Edite Rio M; van Pesch V; Amato MP; Iuliano G; Slee M; Verheul F; Cristiano E; Fernández-Bolaños R; Poehlau D; Saladino ML; Deri N; Cabrera-Gomez J; Vella N; Herbert J; Skromne E; Savino A; Shaw C; Moore F; Vucic S; Petkovska-Boskova T; McDonnell G; Hawkins S; Kee F; Butzkueven H;
Mult Scler; 2014 May; 20(6):739-46. PubMed ID: 24107309
[TBL] [Abstract][Full Text] [Related]
26. The relationship of age with the clinical phenotype in multiple sclerosis.
Scalfari A; Lederer C; Daumer M; Nicholas R; Ebers GC; Muraro PA
Mult Scler; 2016 Nov; 22(13):1750-1758. PubMed ID: 26869531
[TBL] [Abstract][Full Text] [Related]
27. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
28. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
29. Risks of relapse in patients with acute anterior uveitis.
Natkunarajah M; Kaptoge S; Edelsten C
Br J Ophthalmol; 2007 Mar; 91(3):330-4. PubMed ID: 17035277
[TBL] [Abstract][Full Text] [Related]
30. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
[TBL] [Abstract][Full Text] [Related]
31. Early relapses, onset of progression, and late outcome in multiple sclerosis.
Scalfari A; Neuhaus A; Daumer M; Deluca GC; Muraro PA; Ebers GC
JAMA Neurol; 2013 Feb; 70(2):214-22. PubMed ID: 23407713
[TBL] [Abstract][Full Text] [Related]
32. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
[TBL] [Abstract][Full Text] [Related]
33. Impact of multiple sclerosis relapse: The NARCOMS participant perspective.
Nickerson M; Cofield SS; Tyry T; Salter AR; Cutter GR; Marrie RA
Mult Scler Relat Disord; 2015 May; 4(3):234-40. PubMed ID: 26008940
[TBL] [Abstract][Full Text] [Related]
34. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
35. Predicting the profile of increasing disability in multiple sclerosis.
Tomassini V; Fanelli F; Prosperini L; Cerqua R; Cavalla P; Pozzilli C
Mult Scler; 2019 Aug; 25(9):1306-1315. PubMed ID: 30070597
[TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews.
Matza LS; Kim K; Phillips G; Zorn K; Chan KS; Smith KC; Mowry EM
Mult Scler Relat Disord; 2019 Jan; 27():139-146. PubMed ID: 30384199
[TBL] [Abstract][Full Text] [Related]
37. Relapses in multiple sclerosis are age- and time-dependent.
Tremlett H; Zhao Y; Joseph J; Devonshire V;
J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1368-74. PubMed ID: 18535026
[TBL] [Abstract][Full Text] [Related]
38. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
39. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.
Spelman T; Gray O; Trojano M; Petersen T; Izquierdo G; Lugaresi A; Hupperts R; Bergamaschi R; Duquette P; Grammond P; Giuliani G; Boz C; Verheul F; Oreja-Guevara C; Barnett M; Grand'Maison F; Edite Rio M; Lechner-Scott J; Van Pesch V; Fernandez Bolanos R; Flechter S; Den Braber-Moerland L; Iuliano G; Amato MP; Slee M; Cristiano E; Saladino ML; Paine M; Vella N; Kasa K; Deri N; Herbert J; Moore F; Petkovska-Boskova T; Alroughani R; Savino A; Shaw C; Vucic S; Santiago V; Bacile EA; Skromne E; Poehlau D; Cabrera-Gomez JA; Lucas R; Butzkueven H
Ann Neurol; 2014 Dec; 76(6):880-90. PubMed ID: 25283272
[TBL] [Abstract][Full Text] [Related]
40. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
